GT Biopharma Files S-1/A Amendment

TL;DR

GT Biopharma filed an S-1/A, updating its registration. Keep an eye on this one.

AI Summary

GT Biopharma, Inc. filed an S-1/A amendment on February 7, 2025, for its registration statement. The company, formerly known as OXIS INTERNATIONAL INC, DDI PHARMACEUTICALS INC, and DIAGNOSTIC DATA INC /DE/, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located at 315 Montgomery Street, San Francisco, CA.

Why It Matters

This filing indicates GT Biopharma is actively pursuing a securities offering or other regulatory actions, which could impact its capital structure and future operations.

Risk Assessment

Risk Level: medium — S-1/A filings often relate to capital raises or significant corporate changes, which inherently carry risks for investors.

Key Numbers

• 333-284032 — SEC File Number (Identifies the specific registration statement)
• 2834 — SIC Code (Indicates industry classification (Pharmaceutical Preparations))

Key Players & Entities

• GT Biopharma, Inc. (company) — Registrant
• OXIS INTERNATIONAL INC (company) — Former Company Name
• DDI PHARMACEUTICALS INC (company) — Former Company Name
• DIAGNOSTIC DATA INC /DE/ (company) — Former Company Name
• Michael Breen (person) — Interim Chief Executive Officer
• 315 Montgomery Street, 10th Floor San Francisco, CA 94104 (location) — Principal Executive Offices
• February 7, 2025 (date) — Filing Date

FAQ

Key Financial Figures

• $0.001 — ”) of our common stock, par value $0.001 per share (“common stock”)
• $2.38 — sumed combined public offering price of $2.38 per share and common warrant (the last
• $0.0001 — of common stock at an exercise price of $0.0001 per share. Each pre-funded warrant is b
• $100,000 — d expenses in an aggregate amount up to $100,000. In addition, we have agreed to issue t
• $390,531 — cement agent fee, will be approximately $390,531. The delivery of the shares of common

Filing Documents

• forms-1a.htm (S-1/A) — 935KB
• ex5-1.htm (EX-5.1) — 23KB
• ex23-1.htm (EX-23.1) — 5KB
• forms-1_009.jpg (GRAPHIC) — 12KB
• forms-1_001.jpg (GRAPHIC) — 10KB
• vi_001.jpg (GRAPHIC) — 178KB
• vi_002.jpg (GRAPHIC) — 167KB
• vi_003.jpg (GRAPHIC) — 37KB
• vi_004.jpg (GRAPHIC) — 70KB
• vi_005.jpg (GRAPHIC) — 74KB
• vi_006.jpg (GRAPHIC) — 80KB
• ex5-1_001.jpg (GRAPHIC) — 6KB
• 0001493152-25-005314.txt ( ) — 1838KB

DILUTION

DILUTION 16 EXECUTIVE COMPENSATION 17 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 22 SECURITY 23 DESCRIPTION OF CAPITAL STOCK 24 description of securities we are offering 27 MATERIAL TAX CONSIDERATIONS 30 PLAN OF DISTRIBUTION 36 I ncorporation of certain information by reference 39 WHERE YOU CAN FIND MORE INFORMATION 40 LEGAL MATTERS 40 EXPERTS 40 i ABOUT THIS PROSPECTUS We incorporate by reference important information into this prospectus. You may obtain the information incorporated by reference without charge by following the instructions under “ Where You Can Find More Information.” You should carefully read this prospectus as well as additional information described under “ Incorporation of Certain Information by Reference ,” before deciding to invest in our securities. We have not, and the placement agent has not, authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, and only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. The information incorporated by reference or provided in this prospectus contains statistical data and estimates, including those relating to market size and competitive position of the markets in which we participate, that we obtained from o

View Full Filing

View this S-1/A filing on SEC EDGAR